Oncoinfo· @Oncoinfo_it · X·· 13 hours agoScore70
Body
#ESMO26 | Izalontamab brengitecan nel carcinoma avanzato recidivante o metastatico HR+/HER- pre-trattato: l'efficacia di questo nuovo ADC è chiara, ma il vero interrogativo è un altro... 🤔
Armando Orlandi su PANKU-Breast01👇
#OncoSTEPS #metastaticbreastcancer #mBC #ADCs
18 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Oncoinfo · x.com